
Will Viking Therapeutics be acquired before 2027?
Which companies will be acquired before 2027?
AI analysis
This market resolves Yes if Viking Therapeutics (VKTX) is announced as acquired before 31 December 2026; a public deal announcement counts, rumors do not. The 9% price reflects skepticism: VKTX has no large pharma partner, and its lead asset VK2735 (oral and subcutaneous GLP-1/GIP agonist) is still in clinical development, making an acquisition expensive and risky for a buyer.
Our 18% estimate rests on several drivers. First, obesity remains the hottest M&A vertical: Novo Nordisk, Eli Lilly, Roche, AstraZeneca and Pfizer are actively buying assets after the semaglutide and tirzepatide success. Second, VKTX's market cap after the 2024–2025 correction makes it an accessible target for companies wanting an oral GLP-1 without early-stage development costs. Third, the historical base rate: biotechs with positive Phase 2 obesity data show a materially elevated probability of a deal within 18–24 months.
The market may be underestimating how quickly large players are closing portfolio gaps. For Yes to win, we need either public strategic interest or a deal after Phase 3 data readouts. Risks: dilution, trial failure, or management's inflated price expectations — any of these could keep the price below 9%.
Not investment advice. Trade at your own risk.